Psychiatr. pro Praxi, 2006; 1: 43-49

Jaká je budoucnost quetiapinu?

MUDr. Jiří Masopust1, MUDr. Ing. Aleš Urban1, MUDr. Martin Vališ2
1 Psychiatrická klinika LF UK a FN Hradec Králové
2 Neurologická klinika LF UK a FN v Hradci Králové

Quetiapin je registrován pro léčbu akutních a chronických psychóz včetně schizofrenie a léčbu manické epizody bipolární afektivní poruchy. Novou indikací je léčba psychotických komplikací dopaminergní terapie Parkinsonovy nemoci. Výsledky otevřených studií společně s výhodným profilem nežádoucích účinků jsou slibné pro využití quetiapinu také v dalších indikacích. Zkoušen je v terapii psychotických příznaků u demence s Lewyho tělísky a psychotických příznaků a poruch chování u ostatních demencí. Tyto postupy se opírají více o klinickou zkušenost než důsledně ověřené důkazy. Popisujeme rizika podávání antipsychotik starším nemocným s demencí včetně cerebrovaskulárních komplikací.

Keywords: Klíčová slova: quetiapin, antipsychotika II. generace, Parkinsonova nemoc, demence s Lewyho tělísky, extrapyramidové příznaky, cerebrovaskulární komplikace.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J, Urban A, Vališ M. Jaká je budoucnost quetiapinu? Psychiatr. praxi. 2006;7(1):43-49.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aarsland D, Perry R, Larsen JP, McKeith G, O'Brien JT, Perry EK, Burn D, Ballard CG. Neuroleptic sensitivity in Parkinson's disease and Parkinson dementias. J Clin Psychiatry 2005; 66: 633-637. Go to original source... Go to PubMed...
    2. Adityanjee, Schulz SCH. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002; 63(suppl 13): 32-38.
    3. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Expert konsensus panel for using antipsychotic drugs in older patiens. J Clin Psychiatry 2004; 65(suppl 2): 5-99.
    4. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330: 874. Go to original source... Go to PubMed...
    5. Baskys A. Lewy body dementi: The litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry 2004; 65(suppl 11): 16-22.
    6. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 2005; 21: 1-10. Go to original source... Go to PubMed...
    7. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14: 484-487. Go to original source... Go to PubMed...
    8. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513-515. Go to original source... Go to PubMed...
    9. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26: 643-659. Go to original source... Go to PubMed...
    10. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003; 18: 510-514. Go to original source... Go to PubMed...
    11. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004; 3: 4. Go to original source... Go to PubMed...
    12. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004; 50: 433-440. Go to original source... Go to PubMed...
    13. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand SLT, Gurwitz JH, Marras C, Wodchis WP, Mamdani M. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445. Go to original source... Go to PubMed...
    14. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine a clozapine: komparative effects on motor function in hallucinating PD patiens. Neurology 2000; 55: 748-749. Go to original source... Go to PubMed...
    15. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Human Psychopharmacology 2004; 19:205-207. Go to original source... Go to PubMed...
    16. Herrmann N, Mamdani M, Lanctot KL. Atypical Antipsychotic and Risk of Cerebrovascular Accidents. Am J Psychiatry 2004;161: 1113-1115. Go to original source... Go to PubMed...
    17. Horáček J. Mechanizmus účinku atypických antipsychotik a neurobiologie schizofrenie. Psychiatrie 2004; 8: 293-303.
    18. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LR, Jou HCH, Yeung PP. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19: 29-35. Go to original source... Go to PubMed...
    19. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 2004; 75: 295-297.
    20. Kulisevsky J, Roldan E. Hallucinations and sleep disturbances in Parkinson's disease. Neurology 2004; 63(Suppl 3): S28-S30. Go to original source... Go to PubMed...
    21. Lawlor BA. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. J Clin Psychiatry 2004; 65(Suppl 11): 5-10.
    22. Morgante L, Epifano A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, a Spina P, Quattrone A. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27: 153-156. Go to original source... Go to PubMed...
    23. Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 659-665. Go to original source... Go to PubMed...
    24. Movement Disorders Task Force. Drugs to treat dementia and psychosis. Mov Disord 2002; 17(Suppl 4): S120-S127. Go to original source... Go to PubMed...
    25. Ondo WG, Tintner R, Dat Voung K, Lai D, Ringholz G.Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20: 958-963. Go to original source... Go to PubMed...
    26. Peck P. Quetiapine reduces dementia-associated agitation in elderly patients. Medscape Medical News 2004. www.medscape.com/viewarticle/484050.
    27. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse (letter). Am J Psychiatry 2004; 161: 1718. Go to original source... Go to PubMed...
    28. Poewe W. Psychosis in Parkinson's disease. Mov Disord 2003; 18(Suppl 6): S80-87. Go to original source... Go to PubMed...
    29. Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson's disease. Expert Opin Pharmacother 2003; 4: 1747-1761. Go to original source... Go to PubMed...
    30. Rosack J. Antipsychotic do not appear to increase stroke risk. Psychiatric News 2004;39:22. Go to original source...
    31. Sacchetti E, Valsecchi P. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol 2003; 18: 357-359. Go to original source... Go to PubMed...
    32. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596-608. Go to original source... Go to PubMed...
    33. Schrag A. Psychiatric aspects of Parkinson's disease. An update. J Neurol 2004; 251: 795-804. Go to original source... Go to PubMed...
    34. Stahl SM. Essential Psychopharmacology. The prescriber's guide. Cambridge: Cambridge University Press 2005; 571.
    35. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004; 65(Suppl 11): 11-15.
    36. Taylor D, McConnell H, McConnell D, et al. The Maudsley prescribing guidelines. 6th ed. London: Martin Dunitz Ltd 2001; 221.
    37. Urban A, Masopust J, Malý R. Prolaktin jako faktor zvýšené agregace destiček. Psychiatrie 2005; 9: 56-59.
    38. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999; 14: 459-466. Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.